{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28two-dose%29&page=2",
    "query": {
      "intervention": "Placebo (two-dose)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28two-dose%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T15:09:50.432Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04932512",
      "title": "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steatohepatitis, Nonalcoholic"
      ],
      "interventions": [
        {
          "name": "ION224",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 160,
      "start_date": "2021-06-17",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 50,
      "location_summary": "Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 43 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04932512"
    },
    {
      "nct_id": "NCT04511819",
      "title": "Losmapimod Safety and Efficacy in COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Losmapimod oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fulcrum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2020-08-28",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 7,
      "location_summary": "Irvine, California • Miami, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511819"
    },
    {
      "nct_id": "NCT07507370",
      "title": "CARED : A Novel Rapid Treatment Paradigm for Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Intermittent Theta Burst Stimulation (iTBS)",
          "type": "DEVICE"
        },
        {
          "name": "Transcranial Alternating Current Stimulation (tACS)",
          "type": "DEVICE"
        },
        {
          "name": "Psychotherapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sham (Placebo) Transcranial Alternating Current Stimulation (tACS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-04-14",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07507370"
    },
    {
      "nct_id": "NCT06667700",
      "title": "A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease (COVID-19)"
      ],
      "interventions": [
        {
          "name": "Molnupiravir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3082,
      "start_date": "2024-12-02",
      "completion_date": "2031-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 71,
      "location_summary": "Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Castroville",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06667700"
    },
    {
      "nct_id": "NCT04250337",
      "title": "Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Topical Corticosteroid",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2020-02-03",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 43,
      "location_summary": "Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04250337"
    },
    {
      "nct_id": "NCT01239069",
      "title": "Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "DE-110 ophthalmic suspension high dose",
          "type": "DRUG"
        },
        {
          "name": "DE-110 ophthalmic suspension low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2010-11",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2014-05-21",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 14,
      "location_summary": "Inglewood, California • Newport Beach, California • Petaluma, California + 11 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Bloomfield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01239069"
    },
    {
      "nct_id": "NCT00894322",
      "title": "A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide once weekly",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "19 Years to 75 Years"
      },
      "enrollment_count": 65,
      "start_date": "2009-04",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2015-09-18",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00894322"
    },
    {
      "nct_id": "NCT00645177",
      "title": "Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ABT-869",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo for ABT-869",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2008-07",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-29",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Harvey, Illinois",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00645177"
    },
    {
      "nct_id": "NCT05032066",
      "title": "A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "HZN-825",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2022-01-20",
      "completion_date": "2025-01-02",
      "has_results": true,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Palm Springs, California • Clearwater, Florida + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05032066"
    },
    {
      "nct_id": "NCT02065622",
      "title": "Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 952,
      "start_date": "2014-03-27",
      "completion_date": "2019-11-11",
      "has_results": true,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-09-28T15:09:50.432Z",
      "location_count": 42,
      "location_summary": "Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065622"
    }
  ]
}